Good morning, and welcome to the 2026 annual meeting of shareholders of AxoGen Incorporated. I'm Michael Dale, President, Chief Executive Officer, and a Director of AxoGen. We are pleased to host this meeting virtually again this year, allowing broader participation from our shareholders. Before we begin the formal portion of the meeting, I'd like to introduce the members of our Board of Directors. Paul Thomas, Chairman of the Board, William Burke, Chair of the Audit Committee, John Johnson, Chair of the Quality, Compliance, and Portfolio Management Committee, Amy Wendell, Chair of the Compensation Committee, Kathy Weiler, Chair of the Governance, Nominating, and Sustainability Committee, Alan Levine, and Joseph Tyndall. We are also joined today by representatives from Deloitte & Touche, our independent registered public accounting firm, Morrison & Foerster, our outside legal counsel, Broadridge Financial Solutions, represented by Christopher Woods, who is serving as the Inspector of Elections.
From AxoGen's management team, we have Lindsey Hartley, Chief Financial Officer, Marc Began, General Counsel and Chief Compliance Officer. I now call the 2026 annual meeting of shareholders of AxoGen Incorporated to order. I will turn the meeting over to Marc Began, who will serve as Secretary of the Meeting.
Thank you, Michael. We are conducting this meeting in accordance with our bylaws and applicable law. The notice of meeting and proxy statement dated April 29, 2026, were made available to all shareholders of record as of April 24, 2026. Only shareholders of record at the close of business on that date are entitled to vote. Let me summarize some of the procedural points before we begin the formal business portion of the meeting. First, we are recording this meeting, and you will be able to replay a recording of it for one month from the date of the annual meeting on the virtual shareholder meeting website set forth in the proxy statement. Please allow a day or so following the meeting for the recording to be uploaded. Second, you may use the question box on your screen to submit questions at any time during the meeting.
We cannot guarantee that we will answer all questions, but we will do our best. Depending on the time remaining and the nature of the questions, we may use our discretion in determining which questions to answer. Third, you may vote during this meeting at any time from the beginning of the meeting through presentation of the proposals until the polls are closed. However, if you have voted already by proxy or online ballot, a vote cast during this meeting will supersede your earlier vote. If you have already voted and do not wish to change your vote, you do not need to vote again. Fourth, we may temporarily adjourn and reconvene the meeting in accordance with our bylaws at our discretion, including in the event of any technical difficulties before formal adjournment.
Our rules of conduct for today's meeting, as well as our list of registered shareholders, are available on the virtual shareholder meeting website. As of the record date, there were 53,177,824 shares of common stock outstanding and entitled to vote at the annual meeting. I have received a report from the Inspector of Elections confirming that a quorum is present, either virtually or by proxy. Therefore, we may proceed with the business of the meeting. Prior to this meeting, the Inspector of Elections provided me with a report summarizing the tabulation of votes as of the close of business yesterday, which report will be supplemented by any additional proxies and ballots submitted before the polls close. The polls are now open and will remain open until the conclusion of voting on all proposals. We have three proposals to consider today. First, election of the directors.
Shareholders are being asked to elect the following eight directors to serve until the 2027 annual meeting of shareholders: Michael D. Dale, Amy M. Wendell, William Burke, John H. Johnson, Alan M. Levine, Paul G. Thomas, Joseph Tyndall, and Kathy Weiler. Second proposal, ratification of the appointment of the company's independent registered public accounting firm. The proposal seeks shareholder ratification of Deloitte & Touche as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026. The third proposal, non-binding advisory vote on the named executive officer compensation. This is a non-binding advisory vote to approve the compensation of the company's named executive officers as disclosed in the proxy statement. Does anyone have any questions concerning any of the items of business to be considered at this meeting? If anyone has questions, please submit them through the virtual meeting portal.
Hearing no further questions, we will proceed to voting. As I noted earlier, it is not necessary to vote if you have already submitted your proxy unless you wish to change your vote. If any shareholder desires to cast an additional vote or change a previously submitted vote, please do so now through the virtual meeting portal. The polls are now closed. Prior to this meeting, we received proxies representing approximately 45,364,808 shares, which constitutes a quorum for purposes of conducting business. We will now take a short break while the final tabulations are complete and the voting results are prepared. As it appears that all ballots have now been collected and counted, I will turn the meeting over to the Inspector of Elections to announce the preliminary results.
Thank you, Marc. The preliminary results of the votes are as follows. Each director nominee has received in excess of 90.53% of the votes cast in the affirmative and has been elected. The appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm has been ratified with an excess of 99.84% voting in the affirmative, and the non-binding advisory vote on the executive compensation has been approved with an excess of 96.36% voting in the affirmative. Final voting results will be reported in the company's current report on Form 8-K to be filed within four business days following the meeting.
Thank you, Christopher. That concludes the formal business to be conducted at today's meeting. I will now turn the meeting back over to Michael Dale.
Thank you, Marc. On behalf of the board of directors and the entire AxoGen team, I want to thank everyone for their time and participation today. We remain committed to delivering long-term value to our shareholders as we work to make restoration of peripheral nerve function the expected standard of care. This meeting is now adjourned.
This now concludes the meeting. Thank you for joining, and have a pleasant day.